ArticleCureus2025
Stiff-Person Syndrome: Diagnostic and Therapeutic Insights Into a Rare Autoimmune Neurological Disorder.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Stiff-Person Syndrome: A Comprehensive Review of a Rare Disease with Emphasis on Pathophysiology, Clinical Features, Diagnostic Challenges and Therapeutic Advances.The Yale journal of biology and medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stiff-person syndrome (SPS) is a rare autoimmune neurological disorder that is frequently underrecognized due to overlapping musculoskeletal and neuropsychiatric symptoms, leading to delays in diagnosis. We report a 56-year-old Moroccan woman with a seven-year history of progressive lumbar stiffness and painful, stimulus-sensitive spasms extending to both lower limbs, resulting in marked functional limitation and falls. Serum testing showed markedly elevated anti-glutamic acid decarboxylase (anti-GAD) antibodies (greater than 20,000 U/mL), while the spine MRI revealed only mild degenerative changes, and whole-body positron emission tomography excluded malignancy. Symptomatic therapy with pregabalin and baclofen provided partial relief. Intravenous immunoglobulin was administered at a total dose of 2 g/kg over five days, yielding a substantial reduction in stiffness and spasm frequency; at one month, she demonstrated improved mobility and greater independence. Rituximab was proposed for long-term disease control given disease severity and seropositivity. This case underscores the diagnostic value of anti-GAD testing when imaging is unrevealing and highlights that timely initiation of immunotherapy, together with symptomatic agents and rehabilitation, can meaningfully improve outcomes. A multidisciplinary strategy is essential for sustained functional recovery and quality of life in SPS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.